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Abstract
Familial Mediterranean fever (FMF) is an autosomal recessive inheri-
ted disorder. Articular manifestations are the second most common 
presentation in FMF patients after abdominal pain. Colchicine remains 
the gold standard of therapy for the different aspects of the disease. 
However, about 5-15% of patients experience resistance to colchicine. 
Therefore, physicians were encouraged to try different medications 
and treatment modalities. Biologic agents were used in several FMF 
patients with various clinical presentations including articular invol-
vement. In the majority of those, there was a good clinical response 
with improvement in the quality of life. Adalimumab is an anti-TNF 
alpha agent used conventionally in inflammatory bowel disease and 
rheumatologic disorders. To date only five cases were reported in the 
literature using adalimumab for severe refractory FMF.
Our case report details a young female with severe disabling colchi-
cine-resistant FMF associated with significant articular inflammation. 
She was treated with adalimumab with remarkable clinical improve-
ment and complete response.
The role of Adalimumab in the 
Treatment of Colchicine-Resistant 
Familial Mediterranean Fever 
 CaSe RepoRt 
Iyad Issa1, 
Malak Noureddine1
1  Rafik Hariri University Hospital. 
Department of Gastroenterology and 
Hepatology. Beirut, Lebanon.
Contact information:
Iyad Issa MD.
Address: Specialty Clinics Center 4B. 
Maamari street. Hamra postal code 2034 
7304. Beirut, Lebanon.
 iyadissa71@gmail.com
Keywords
Familial Mediterranean Fever; 
Adalimumab; Colchicine; 
Biologic Agents; 
Anti Tumor Necrosis Factors.
Introduction
Familial Mediterranean fever (FMF) is one of the hereditary auto-in-
flammatory recurrent fever syndromes [1]. Typical FMF attacks mani-
fest as recurrent self-limiting episodes of fever, pleuritis, peritonitis, 
and arthritis [1, 2]. Secondary amyloidosis is the most serious com-
plication in FMF and usually leads to proteinuria and possibly chronic 
renal failure [3].
FMF-associated arthritis is a symmetric mono-oligoarthritis that 
shows a self-limiting course and resolves without sequelae [4]. Howe-
ver, in less than 10% of patients arthritis runs a more complicated pro-
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tracted course leading to functional disability and 
potentially prosthetic joint replacement [5-7]. There 
is a well-established link between FMF and ankylo-
sing spondylitis (AS) where sacro-iliitis prevalence is 
estimated to be 7% in those with musculoskeletal 
manifestations [8]. The exact role of HLA-B27 in 
the development of sacro-iliitis is still controversial 
[8, 9]. On the other hand, it has been established 
that M694V mutation is associated with the most 
severe clinical form of FMF. Additionally, it has also 
been linked to the occurrence of arthritis [8, 10, 11].
Colchicine remains the mainstay of therapy in 
FMF patients, except for the 5-15% of patients 
who appear to be resistant to this therapy [12, 13]. 
Biologic agents have shown significant impact on 
symptoms improvement as well as a positive effect 
on the quality of life. In addition, they appear to play 
a role in amyloidosis prevention [14-20]. We hereby 
present a patient who had severe manifestations 
of FMF and arthritis despite treatment with anti-
inflammatory agents and colchicine, but showed a 
dramatically positive response upon administration 
of adalimumab.
Case report
A 34-year-old Palestinian female patient homo-
zygous for M694V mutation in the MEFV gene, 
diagnosed with FMF at the age of 24 presented to 
our care. She reported severe myalgias and arthral-
gias with large joint arthritis involving mainly the 
back and the knees. She was maintained on col-
chicine 1mg three times daily and naproxen 500mg 
three times daily, plus paracetamol 1gm three times 
daily and as needed. The patient had tried multiple 
short courses of steroids which provided her with 
only minimal transient relief.
Despite all those medications, she continued to 
experience recurrent attacks of severe abdominal 
pain, chest pain, and high grade fever each lasting 
2-3 days, with a frequency of up to 6 times per 
month. In addition, she reported daily arthralgia 
and joint stiffness mainly around the large joints. 
Her biochemical inflammatory profile showed sig-
nificant elevations in ESR and CRP and mild anemia 
(table 1). She was noted to be depressed, in cons-
tant low mood due to a severe uncontrollable di-
sease which significantly affected her social life and 
daily tasks. After consulting with her rheumatologist 
we decided to attempt treatment with adalimumab. 
She was started on 40mg subcutaneous injections 
every 2 weeks and both colchicine and naproxen 
doses were reduced. At week 8 she reported a sig-
nificant decrease in the number of FMF episodes, 
joint stiffness and arthralgia. So, the treatment was 
maintained and both colchicine and naproxen were 
further decreased to once daily. 6 months later ge-
neral improvement was subjectively reported to be 
85% and she was able to move freely with minimal 
joint stiffness and she mentioned a total of 4 mild 
episodes of pain and fever. During all that period 
she was also off naproxen and her biochemical pro-
file revealed a substantial decrease in acute phase 
reactants. At 1 year of treatment her medical insu-
rance ceased financial coverage of her medication 
and the patient was forced to stop her regimen and 
go back to the previous drugs. Her medical status 
deteriorated fast and within 2 months she was back 
to her pre-treatment condition. The laboratory fin-
dings of the patient at different stages of follow-up 
are shown in Table 1.
Table 1.  The laboratory results of the patient during 
different stages of follow-up..
Before 
treatment
6 months 
Follow up
After 
stopping 
treatment
ESR 83 32 54
C-reactive protein
 (mg/l)
39 8 28
Hemoglobin (g/dl) 11.1 12.9 11.8
Platelets 332000 308000 392000
Creatinine (mg/dl) 1.1 1.0 1.0
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Discussion
We reported a case of FMF with coexisting spon-
dyloarhtropathy and large joint arthritis in a patient 
who suffered from severe abdominal pain attacks 
despite maximal use of colchicine and anti-inflam-
matory agents. Once adalimumab was started, mar-
ked improvement in her symptoms occurred. Her 
quality of life changed substantially with almost 
complete resolution of her articular pain and ab-
dominal attacks. The therapy was considered to be 
efficacious, well tolerated, with no reported side 
effects.
It is estimated that 70-75% of FMF patients have 
articular involvement, with serositis as the most 
common manifestation [21]. The joint involvement 
subsides within days, however in about 5% of pa-
tients destructive arthritis involving mainly the large 
joints many ensue [22]. The mainstay medication 
for treatment of FMF and amyloidosis prophylaxis 
is colchicine at a dose of 1.5-2mg daily [23, 24]. 
However, in 5 to 15% of patients treatment fails 
and they get labeled as non-responders. In these 
patients compliance should be checked and rein-
forced as it may be the causative agent [12, 13, 23, 
25]. Multiple genetic and pharmacological factors 
play a role in true non-responders and they are not 
well clarified yet [23, 26].
The pathogenesis of FMF starts from the MEFV 
gene mutation that leads to increased synthesis of 
mutated pyrin. As a consequence, an inappropriate 
full-blown inflammation occurs. The activation of 
IL-1β is mediated by an inflammatory trigger leading 
to the induction of an inflammasome [27]. TNF-
alpha plays a role in the mediation of the inflam-
matory cascade. Consequently, blocking this factor 
might lead to the reversal of the inflammation [28]. 
Nonetheless, previous studies have shown variable 
levels of TNF-alpha in FMF patients confusing the 
picture. Thus, their exact role has not yet been well 
clarified [29, 30]. Despite these controversies, the 
efficacy and safety of anti-TNF alpha agents in the 
treatment of resistant FMF patients in different case 
reports and case series is an evidence of a potential 
major role of TNF-alpha in FMF pathogenesis [14-
20].
Data derived from the efficacy of biologics in 
treatment of various rheumatological diseases had 
encouraged clinicians to use them in resistant FMF 
cases [14-20, 31]. There are several case reports to 
date that use anti-TNF agents in the treatment of 
FMF. The most commonly used agent is etanercept 
followed by infliximab. In all these cases, a favorable 
response with complete resolution of the clinical 
manifestations as well as normalization of the acute 
phase reactants was recorded [14-20].
Literature review yielded only five reported cases 
for the use of adalimumab in FMF patients [16, 17, 
19]. Our case shares many of the characteristics 
with those cases including the age, the presence 
of peripheral arthropathy, the genetic mutation, 
the colchicine resistance, and the marked impro-
vement upon the initiation of adalimumab. The 
personal characteristics of the published cases, cli-
nical presentation, genetic backgrounds, as well 
as their disease course after starting adalimumab 
are listed in Table 2. It seems even patients with 
Table 2.  Characteristics of the reported cases in the literature.
Age G C R S G P A MEFV HLA B27 BASDAI* BASDAI** Disease course
42 M + 3-4 - M694V - 5.9 1.3 Attacks duration & frequency decreased
31 F + 2 + M694V/V726A + 7.1 2.0 Attacks disappeared
24 F + 3 - M694V + 7.4 3.2 Attacks disappeared & arthritis improved
37 M + 4 + M694V + 5.0 1.7 Attacks disappeared & arthritis improved
48 F + 4 - M694V/M680I - 5.2 1.2 Attacks decreased & arthritis improved
G = gender, C R = colchicine resistance, S G = Sacro-iliitis grade, P A = peripheral arthritis, BASDAI* = before Rx, BASDAI** = 2 months on Rx.
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bad prognostic phenotypes had a good chance of 
response to adalimumab.
Conclusion
Colchicine remains the only Food and Drug Admi-
nistration approved medication for the treatment of 
different FMF patients. It is also the only approved 
medication against FMF complications and namely 
amyloidosis. Biologic agents appear to have a valid 
future role in the management of colchicine-resis-
tant FMF cases. Several case reports and series had 
demonstrated the use of anti-TNF agents and alpha 
integrin blockers. Nonetheless, to be considered 
valid treatment options well designed randomized 
controlled trails are needed. Therefore until then and 
because of the serious side effects of these agents 
caution and selectivity must dictate their use.
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